US92532F1003 - Common Stock
VERTEX PHARMACEUTICALS INC
NASDAQ:VRTX (5/17/2024, 7:00:02 PM)
After market: 445.21 0 (0%)445.21
+4.57 (+1.04%)
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 4,800 full-time employees. The firm is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The firm has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210
P: 16173416393
CEO: Reshma Kewalramani
Employees: 4800
Website: https://www.vrtx.com/
Last week, Bluebird Bio (NASDAQ:BLUE) shares climbed while CRISPR Therapeutics (NASDAQ:CRSP) stock fell back. The latter has since spiked, while Bluebird Bio has given back many of its gains from the previous week. Did the market simply make a mistake? I’m not sure, but I’m certainly more bullish on CRISPR Therapeutics, with the company offering a cheaper and more commercially viable gene-editing treatment than Bluebird Bio. Meanwhile, I’m neutral on Bluebird Bio. Bluebird Bio vs. CRISPR Therape
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.
How much would you pay for a stock that might earn $25 a year in six years?
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.
Here you can normally see the latest stock twits on VRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: